Blog

Jayastu Senapati: Check out our poster on display at ASH23

Photo from Jayastu Senapati/X

Dec 15, 2023, 06:27

Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared on X/Twitter:

“Check out our poster on display today at the American Society of Hematology (ASH23).
-High-risk cytogenetics (HG-CTG) loses prognostic impact with inotuzumab ozogamicin (InO) and blinatumomab (Blina) added to frontline HyperCVAD chemotherapy in newly diagnosed patients with Philadelphia negative B-cell Acute Lymphoblastic Leukemia.
-Further analysis underway.”

Source: Jayastu Senapati/X

Acute Lymphoblastic Leukemia American Society of Hematology ASH23 blinatumomab cancer High-risk cytogenetics (HG-CTG) HyperCVAD inotuzumab ozogamicin Jayastu Senapati MD Anderson Cancer Center OncoDaily Oncology

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage